Build a South Korean vitiligo treatment budget from actual NB-UVB and 308 nm excimer patient charges, provider-confirmed coverage status, visits, travel, time, and a contingency reserve.
This calculator never assigns NHI coverage from lesion location alone. Enter the provider-confirmed status and the actual patient amount for each treatment line.
Complete only the treatment lines in the clinician-proposed plan. Twelve weeks is an interface starting point, not a recommended course.
Use the period supplied by the treating team. It is used only for the average weekly session figure.
Use this line for 311 nm NB-UVB or another itemized dermatological UV treatment under the MM331–MM334 context.
For covered care enter the actual copay after NHI. For non-covered care enter the full disclosed charge.
Use the provider quote for the N0131–N0133 skin laser therapy context.
Do not derive a price from lesion area or an online quote. Enter the provider-specific patient amount.
This removes only duplicate visits and is capped at the smaller treatment-session count.
Do not duplicate an item already included in the session price or package.
The deduction is capped at combined phototherapy and excimer session charges.
Do not enter the NHI-funded portion again. Use only an additional KRW payment that is confirmed.
These optional fields show household burden beyond the medical bill.
Count only visits that do not overlap a treatment or separate follow-up visit.
This is a budgeting buffer, not a treatment recommendation.
A single phototherapy or excimer receipt does not show the cost of a repeated treatment plan.
Narrowband UVB and 308 nm excimer sessions may continue across many visits, while consultation, diagnostic work, medicine, and follow-up can be included in or billed outside the session quote.
This calculator keeps those lines separate, removes duplicate visits when both treatments occur on the same day, and adds optional travel, time, and contingency costs.
For a covered service, enter the actual patient share after the National Health Insurance funded portion, not the total allowed medical charge.
For a non-covered service, enter the full amount disclosed by the provider.
If the status is not yet confirmed, keep it as unknown instead of inferring coverage from the diagnosis or lesion location.
The Korea Disease Control and Prevention Agency describes narrowband UVB as 311 nm ultraviolet B treatment.
Dermatological ultraviolet therapy codes MM331 through MM334 divide the billed service by the treated body-area band, and vitiligo is a named indication.
Ministry of Health and Welfare Notice No. 2015-139 recognizes up to three covered sessions per week, while the treating dermatologist still decides the individual schedule and exposure.
KDCA describes excimer as targeted light delivered to vitiligo lesions while limiting exposure of unaffected skin.
HIRA materials place 308 nm excimer under skin laser therapy codes N0131 through N0133 when the stated provider and disease conditions are satisfied.
The lesion-area code is a billing context, not a self-service price table, so this calculator never converts square centimetres into a national price.
KDCA notes that narrowband UVB is commonly delivered two or three times a week and that at least three months may be needed before assessing response.
Individual duration varies, so the calculator uses 12 weeks only as an editable interface starting point for an average-session display.
Replace it with the current planning window supplied by the treating team.
The following table summarizes official material checked on July 27, 2026.
It does not guarantee a claim because the actual lesion, performed service, provider conditions, and itemized billing record remain controlling.
| Treatment context | Code or source | Confirmation point | Frequency or area |
|---|---|---|---|
| General vitiligo treatment | Notice No. 2013-69 | Exposed areas and connected lesions under the general rule | Service-specific |
| Dermatological UV therapy | MM331–MM334, Notice No. 2015-139 | Vitiligo indication and a resident dermatologist | Up to 3 per week |
| 308 nm excimer | N0131–N0133, Notice No. 2005-38 | Actual lesion on face, neck, hands, arms, or below the knees | Under 10, 10–50, or at least 50 cm² |
Notice No. 2013-69, effective April 30, 2013, distinguishes general vitiligo treatment from locally delivered excimer.
The general rule refers to exposed areas and connected lesions, but excimer coverage is limited to lesions actually located on the face, neck, hands, arms, or below the knees.
Select a covered excimer line only after the provider confirms the billing status for the actual treated lesion.
Twenty-four UVB sessions plus twelve excimer sessions equal thirty-six treatment sessions.
If eight pairs occur on the same day, the number of treatment visits is `24 + 12 - 8 = 28`.
The overlap field reduces only travel and time visits; it never removes either medical treatment charge.
Enter the patient amount for initial consultation and clinician-ordered diagnostic work, such as a Wood lamp examination, only when it is outside the session quote.
Count follow-up visits separately only when they do not occur on a treatment day.
Place prescription medicine, topical products, and supplies in other medical cost when they are not already included.
Enter only a package discount confirmed as a KRW total by the provider.
Enter an additional payment only after an insurer, employer, or support program confirms the amount.
Never enter the NHI-funded portion again because a covered session amount already excludes it.
Session charges = UVB sessions × UVB patient amount + excimer sessions × excimer patient amount
Net medical cost = medical cost before discount - applied package discount - applied confirmed reimbursement
Treatment visits = UVB sessions + excimer sessions - applied same-day overlap
Funding target = net medical cost + travel + time cost + medical contingency
Monthly target = ceiling of funding target ÷ funding months
This example exists only to test the arithmetic.
It is not a Korean national average, recommended schedule, coverage precedent, or private-insurance outcome.
All session and price inputs in the live calculator start at zero.
| Line | Input or equation | Amount or count |
|---|---|---|
| Covered NB-UVB patient share | 24 sessions × KRW 8,000 | KRW 192,000 |
| Confirmed non-covered excimer | 12 sessions × KRW 25,000 | KRW 300,000 |
| Other medical lines | KRW 50,000 initial + KRW 60,000 follow-up + KRW 90,000 other | KRW 200,000 |
| Net medical cost | KRW 692,000 - KRW 60,000 discount - KRW 100,000 reimbursement | KRW 532,000 |
| Total visits | 36 sessions - 8 same-day pairs + 3 follow-ups + 2 other visits | 33 visits |
| Travel and time | KRW 330,000 travel + 49.5 hours × KRW 15,000 | KRW 1,072,500 |
| Funding target | Includes KRW 53,200 medical contingency | KRW 1,657,700 |
| Monthly funding | Ceiling of KRW 1,657,700 ÷ 6 months | KRW 276,284 |
The example produces KRW 14,778 as average net medical cost per treatment session and three total treatment sessions per planning week.
That weekly figure combines both treatment lines and does not decide a medically appropriate frequency.
If time cost is not part of the household budget, leave the hourly value at zero.
Do not label the entire plan covered from one diagnosis. Use the provider-confirmed patient amounts, and calculate separate scenarios if the itemized quote splits locations or services.
Keep both medical session charges, then enter the paired visit count once. This avoids understating medical cost while preventing duplicate travel and time cost.
List every included consultation, test, and follow-up before comparing. Apply only the confirmed KRW discount and remove any line already included in the package.
Add round-trip transport, visit hours, and an actual hourly wage loss or chosen time value to reveal burden outside the medical receipt.
Article 9 of the current National Health Insurance medical-care benefit rule, MST 285513 effective April 15, 2026, connects non-covered subjects to Annex 2.
Medical Service Act Articles 45 and 45-2, MST 285327 effective April 7, 2026, provide the non-covered disclosure and reporting framework.
Enforcement Rule Articles 42-2 and 42-3, MST 286963 effective June 12, 2026, require accessible price information and set reporting details.
A provider website price may still differ in date or included services, so compare the current written quote, itemized statement, and receipt before relying on the result.
No. The HIRA rule limits the excimer coverage context to actual lesions on the face, neck, hands, arms, or below the knees. The provider must still confirm the performed service and billing status.
Do not assume that result. The general treatment rule mentions connected lesions, but the excimer paragraph narrows coverage to lesions actually located on the listed exposed sites.
No. Enter only the actual patient share after the NHI-funded portion. Add separately billed consultation or tests once, after checking whether the session quote already includes them.
No. If a provider-confirmed covered UVB plan averages more than three per week, the result warns you to confirm the Notice No. 2015-139 recognition limit and the actual claim plan. Clinical scheduling remains with the treating team.
No. Contract generation, coverage classification, deductibles, and claim review vary. Enter only an additional KRW payment that the insurer has confirmed.
Only as a temporary arithmetic check. The final budget should use the current provider quote because lesion area, included consultation, institution, and coverage status can differ.
No. Both session charges remain. Same-day overlap removes only one duplicate visit from travel and time calculations.
No. Treatment purpose, the person who paid, salary thresholds, and evidence require separate review. Use the medical-expense calculator and year-end tax records instead of deducting a generic percentage here.
Sources were checked July 27, 2026, and no provider price was converted into a national default.
Future maintainers must update the guide, constants, and tests together if the rule, notice, code, or coverage boundary changes.
Separate the treatment lines and coverage statuses first, then add visit overlap and household costs.
Treat each warning as a provider question so the final budget reflects the actual Korean bill rather than a generic online price.